MTAP and glioblastoma: Overall, we found loss of MTAP expression in 45.95% (233/507) of cases, this being observed in 27.8% (5/18) of diffuse astrocytoma, 50.0% (12/24) of anaplastic astrocytoma, 45.6% (193/423) of adult glioblastoma, and 54.8% (23/42) of pediatric glioblastoma (Figure 3A–E).